Our understanding of the genetic basis of myeloproliferative neoplasms began in 2005,
when the JAK2 (V617F) mutation was identified in polycythemia vera, essential …

Disease-specific mutations facilitate diagnostic precision and drug target discovery. In
myeloproliferative neoplasms (MPN), this is best exemplified by the chronic myeloid …

Myeloproliferative neoplasms (MPNs) are diseases caused by mutations in the
haematopoietic stem cell (HSC) compartment. Most MPN patients have a common acquired …

Genomic studies have identified somatic alterations in the majority of myeloproliferative
neoplasms (MPN) patients, including JAK2 mutations in the majority of MPN patients and …

Mutations in the calreticulin (CALR) gene were recently discovered in patients with essential
thrombocythemia (ET) lacking the JAK2 V617F and MPL W515 mutations, but no information …

Myeloproliferative neoplasms, including polycythemia vera (PV), essential thrombocythemia,
and myelofibrosis (MF)(both primary and secondary), are recognized for their burdensome …

Obesity markedly increases susceptibility to a range of diseases and simultaneously
undermines the viability and fate selection of haematopoietic stem cells (HSCs), and thus …

Our understanding of the genetic basis of the Philadelphia chromosome-negative
myeloproliferative neoplasms (MPNs) has moved forward at a staggering pace over the last …

Symptom burden in myeloproliferative neoplasms (MPNs) is heterogeneous even among
patients within the same MPN diagnosis. Using cluster analysis from prospectively gathered …

Mutations in the gene calreticulin (CALR) occur in the majority of JAK2-and MPL-unmutated
patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF); identifying …